Sign inJoin waitlistJoin the waitlist

Fiona Simpkins

Director of Clinical & Translational Gynecologic Oncology Research, Penn Medicine Health System · University of Pennsylvania Health System

Credentials: · · · · · ·

History

Penn Medicine Health System · University of Pennsylvania Health System
Present
University of Pennsylvania Health System
Present
University of Pennsylvania Health System
Present

Cleveland Clinic Foundation
2005–2008
2005–2008
National Cancer Institute
2003–2005
Obstetrics and Gynecology
Johns Hopkins Hospital
2001–2005
Temple University School of Medicine
1995–1999

Research

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Nature Communications · 2020 · Last of 21 authors · Corresponding · 326 citations
Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models
Clinical Cancer Research · 2017 · Last of 10 authors · 266 citations
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
Cell Reports · 2017 · 146 citations

Emily Ko
16 papers · 7 as a resident
Erin George
11 papers · 3 as a fellow
Gordon Mills
11 papers
Robert Giuntoli
11 papers
Dimitrios Nasioudis
9 papers · 7 as a resident
Mark Morgan
9 papers
Lilie Lin
8 papers
Lauren Schwartz
7 papers
Ronny Drapkin
7 papers
Anna Smith
6 papers · 3 as a fellow
Janos Tanyi
6 papers
Lainie Martin
6 papers

Grants

SPORE in Ovarian Cancer
National Cancer Institute · P50
Project lead · $2.9M · Johns Hopkins University
2018–2029
Developing Biomarkers of Response for a New Therapy in Ovarian Cancer
National Cancer Institute · R01
Contact PI · $2M · University of Pennsylvania
2024–2028
University of Pennsylvania Patient-Derived Xenograft Development and Trials Center
National Cancer Institute · U54
Project lead · $1M · University of Pennsylvania
2023–2028
A Novel More Effective Genotoxic Therapy for Ovarian Cancer
National Cancer Institute · R37
Contact PI · $2.6M · University of Pennsylvania
2018–2026

Clinical trials

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2023–2027
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer
Principal investigator · Completed · Phase 2
University of Pennsylvania
2018–2025
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Principal investigator · Active not recruiting · Phase 1
Abramson Cancer Center at Penn Medicine
2016–2028
A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)
Principal investigator · Completed · Phase 1
Abramson Cancer Center at Penn Medicine
2015–2020